Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022

Rhea-AI Summary

Evofem Biosciences (Nasdaq: EVFM) will hold a conference call on May 4, 2022, at 4:30 p.m. ET to discuss its first-quarter 2022 financial results and business highlights. Participants can join the call via phone or webcast. For the phone dial-in, use (877) 407-0890 (U.S. toll-free) or (201) 389-0918. The company is known for its innovative products in women's sexual and reproductive health, including the FDA-approved product, Phexxi®. To learn more, visit phexxi.com.

-- Conference Call Scheduled for 4:30 p.m. ET –

SAN DIEGO, April 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022 as follows:

Date:	Wednesday, May 4, 2022
Time:	4:30 p.m. ET (1:30 p.m. PT)
Live call:	(877) 407-0890 (U.S. toll-free) or (201) 389-0918
Webcast (live and archived) and related slide presentation:	https://evofem.investorroom.com/2022Q1Results or https://www.webcast-eqs.com/evofem20220504/en

Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call using

About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com 
Mobile: (917) 673-5775

Media Contact
Jack Hirschfield
Evofem Biosciences
jhirschfield@evofem.com
Mobile: (512) 674-5163

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2022-results-and-provide-corporate-update-on-wednesday-may-4-2022-301531647.html

SOURCE Evofem Biosciences, Inc.

FAQ

What date will Evofem Biosciences report its Q1 2022 results?

Evofem Biosciences will report its Q1 2022 results on May 4, 2022.

What time is the Evofem Biosciences conference call scheduled for?

The conference call is scheduled for 4:30 p.m. ET.

How can I listen to the Evofem Biosciences Q1 2022 results call?

You can listen to the call by dialing (877) 407-0890 (U.S. toll-free) or through the webcast available on their investor site.

What is Phexxi® developed by Evofem Biosciences?

Phexxi® is a hormone-free, on-demand contraceptive vaginal gel developed by Evofem Biosciences.

Where can I find more information about Evofem Biosciences products?

More information about Evofem Biosciences products can be found at phexxi.com.